• shalafi@lemmy.world
    link
    fedilink
    English
    arrow-up
    5
    ·
    5 days ago

    They can’t be too new or they wouldn’t be anywhere near human trials. Anyway, this is the sort of thing AI (machine learning?) excels at. Not getting excited until we see peer review, but the methodology seems sound (to me, an armchair biologist).

      • shalafi@lemmy.world
        link
        fedilink
        English
        arrow-up
        6
        ·
        5 days ago

        I’m down for that and think it needs expanded. If I’m terminal, I want the choice to be used as an experiment, assuming the FDA finds the treatment somewhat viable.

        Dad had mesothelioma from serving on a WWII destroyer (asbestos wrapped pipes, all those men died by the 80s). He went to some quack in the Bahamas who mixed up snake oil from all his patient’s plasma, patients who later tested positive for AIDS. AIDS hit the public conscious right about when dad died. One wonders…

        • dgdft@lemmy.world
          link
          fedilink
          English
          arrow-up
          4
          ·
          5 days ago

          Yeah, totally agreed.

          It’s a tough balancing act to filter the snake oil while taking viable moonshots, but I think that’s a niche that the US regulatory regime has generally done well on, all things considered.

    • Avicenna@programming.dev
      link
      fedilink
      English
      arrow-up
      2
      ·
      5 days ago

      Yeah my first question was “how the hell did they get approval for a human trial”. Until covid I don’t think you would even be able to get approval for mRNA flu vaccine human trials.